Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?
Executive Summary
Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors
You may also be interested in...
J&J Risperdal Consta “non-approvable”
J&J will discuss FDA concerns about pre-clinical data for injectable long-acting antipsychotic Risperdal Consta (risperidone) following receipt of "non-approvable" letter. J&J filed the NDA Aug. 31, 2001...
Alkermes/Reliant Merger: Can Lescol Follow Altace Model?
Alkermes hopes Lescol will follow the model of King's Altace as a late bloomer in the cardiovascular market following the proposed acquisition of Reliant Pharmaceuticals
Immune Response Remune Trials To Continue After Agouron Drops Rights
Immune Response Corporation will continue clinical trials for the HIV therapy Remune (HIV-1 immunogen) following the decision by Pfizer subsidiary Agouron to drop its rights to develop and market the product, IRC said July 6.